All News
#EULAR2023 #POS1066 “Diagnosis: Seropositive Nodular Rheumatoid Arthritis” - I can probably get rid of Nodular soon in my letter. Trends of Nodules have decreased over time. Could be because we are getting better at preventing erosion and smoking cessation @RheumNow https://t.co/fmQvyNHCUJ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Impact of menopause & on function in RA
HAQ increases slightly after menopause
Premature menopause = worse function
Slightly better HAQ (but moderate & no effects on other PROs) in THR group vs. non THR
No safety data
@RheumNow OP0268 #EULAR23 https://t.co/7KJScF8O2X
Aurelie Najm AurelieRheumo ( View Tweet)
Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w
Janet Pope Janetbirdope ( View Tweet)
#Scleroderma activity index #SCTC has an initial validated tool that is associated with death and organ damage with moderate correlations, so it has some degree of face validity @RheumNow #EULAR2023 @eular_org #OP0235 https://t.co/RDekhr7d2e
Janet Pope Janetbirdope ( View Tweet)
Initial use of glucocorticoids GC as bridging treatment in RA resulted in increase use of GC later, fewer DMARD changes later, van Ouwerkek L, Abst#OP220 #EULAR2023 @RheumNow https://t.co/IjxgQTZ8SE
Dr. Antoni Chan synovialjoints ( View Tweet)
>= 2 tophi and carotid plaque by ultrasound could independently predict major adverse cardiovascular events in addition to conventional CVD risk factors in #gout, data from a single center cohort of 262 pts with 10 yr follow up #EULAR2023 @rheumnow abst#OP0154
Bella Mehta bella_mehta ( View Tweet)
Malignancy in real world datasets:
do we see differences between DMARDs - particularly JAKi, with ORAL Surveillance in mind?
RABBIT German data (limited risk window):
Point estimates slightly up vs TNFi, esp in high CV risk pts
but magnitude not big
OP0218 #EULAR2023 @RheumNow https://t.co/Ou7TgWvf3b
David Liew drdavidliew ( View Tweet)
Scleroderma has an activity index that is associated w future morbidity & mortality. I wonder re the weightings of diff clinical manifestations as scleroderma renal crisis could weigh similarly to ex elevated CRP & a less severe manifestation. OP0235 @RheumNow #EULAR2023 https://t.co/KkimHBDVpg
Janet Pope Janetbirdope ( View Tweet)
#ClinicalPearl Updated #scleroderma Rx recommendations OP0234 New recommendations included ILD, early dcSSc 20 vs prior 16 guidelines. And they recommend ??! Won’t release yet due to importance of wording which will be finalized soon EULAR2023 @RheumNow @eular_org https://t.co/lES6pqkgeT
Janet Pope Janetbirdope ( View Tweet)
The JAK-pot study did not show any significant differences in MACE and other CV outcomes in RA patients treated with JAKi, slight increase signal in VTE/PE, Romain Aymon, Abst#OP0219 #EULAR2023 @RheumNow https://t.co/oPMnw2QmW3
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2023 POS1190-HPR Besides genetic influence, what do patients with #SLE think re: cause of the disease? A survey in N=290 in Sweden showed stress, hormones & infection as the next top 3 causes. Those reported the first two had different education & perceived health @RheumNow https://t.co/GhyCyp7EWU
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
We need to assess CV risk in IA but how?
Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO
Bummer: these 3 prediction tools are less accurate in IA but also OA.
We need a dedicated tool.
@Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm AurelieRheumo ( View Tweet)
Very much looking forward to our joint PRP-HRP-Rheum session later today
How to improve & implement apps for self management in clinical care @ElenaNikiUK @fibrofella @ProfYelizPrior
We will discuss and reveal the results of a survey made for #EULAR23
@RheumNow @eular_org https://t.co/R5vTW3FeWO
Aurelie Najm AurelieRheumo ( View Tweet)
Interesting study presented by Dr Kent Kwoh in #KneeOA using the OAI data - effusion-synovitis produced heterogenous effects on pain reporting depending on the activity - walking, stairs, standing etc. effect not in bone marrow lesions
@rheumnow abst#POS0108 #EULAR2023 https://t.co/MvI5z1KHlE
Bella Mehta bella_mehta ( View Tweet)
Men trying to conceive were prev told to avoid MTX. Another myth busted
Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues!
OP0224 #EULAR2023 @RheumNow (& @ARD_BMJ https://t.co/SDdoNP12oR)
David Liew drdavidliew ( View Tweet)
Early Rx with immunosuppressives doesn’t seem to prevent ILD in #scleroderma ? Chanelling bias as dcSSc get more ILD, esp if active disease but in this side it didn’t make a difference #EULAR2023 @RheumNow OP0239 https://t.co/xt0mtpOpYl
Janet Pope Janetbirdope ( View Tweet)
Phase 2b-human Knee #OA MM-II, a novel suspension of empty large multilamellar liposomes dimyristoylphosphatidylcholine (DMPC)and dipalmitoylphosphatidylcholine (DPPC)- upto 6ml IA injection - well tolerated with minimal AE. some effect on WOMAC @rheumnow #EULAR2023 abs#POS0106 https://t.co/MM8jIG5bkP
Bella Mehta bella_mehta ( View Tweet)
Watch: Baricitinib in Lupus Nephritis
Dr. Peter Nash reports on abstract OP0053 presented at EULAR 2023 in Milan, Italy.
https://t.co/U9sIkCs7dX https://t.co/MgmVHo7wZo
Links:
Dr. John Cush RheumNow ( View Tweet)
Erosive #handOA is associated with more pain and more functional impairment than #RA - 10 year duration, which ofcourse has more comorbidities. 138 OA, 379 RA pts. #EULAR2023 @rheumnow abst#POS0103 https://t.co/mP3Nzgmw07
Bella Mehta bella_mehta ( View Tweet)
Lots of early pipeline data in lupus at #EULAR2023 mainly in the supplement!
AFIMETORAN dual TLR7/8 ANTAGONIST in lupus mice! Maybe steroid sparing! Abst#AB0132
@RheumNow
Bella Mehta bella_mehta ( View Tweet)